Cell and gene therapy CDMO Andelyn Biosciences has manufactured a viral vector for the Nationwide Children’s Hospital’s Cellular Therapy and Cancer Immunology Program.
Created through the company's AAV Curator platform, the adeno-associated virus (AAV) will be used in a novel cell therapy for high-risk acute myeloid leukaemia (AML).
The safety of the novel therapy will be assessed in a forthcoming Phase I clinical trial.
Within the field of cell therapy, there is a consistent need from researchers to manufacture cGMP virus to support the advancements of these critical therapies.
While many AAV manufacturing platforms are specifically designed to be scaled to support large scale indications, Andelyn’s AAV Curator® Platform utilises "Optimization-by-Design" to be correctly sized for scale and speed to the clinic.
The well-established platform allows for the ability to support the exacting viral vector manufacturing needs of the NCH NK cells created on the hospital’s patented universal-donor NK cell platform.
“NCH's Universal Donor CD38KO CD33CAR-NK cell therapy has already proven highly promising, commented Matt Niloff, Chief Commercial Officer at Andelyn. "We look forward to the clinical trial ushering in a new era for patients with AML and other blood cancers.”
Andelyn is enabling the progression of life-altering cell and gene therapies for both rare and prevalent diseases with the highest quality standards and scalable end-to-end development and manufacturing capabilities at its Columbus, Ohio facilities.
